{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:59:45Z","timestamp":1772117985723,"version":"3.50.1"},"reference-count":27,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T00:00:00Z","timestamp":1721520000000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Brain and Behavior"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The objectives of this real\u2010life study were to analyze the reversion of chronic migraine (CM) to episodic migraine (EM) with fremanezumab, evaluate its benefit on the symptomatology, and determine the influence of possible clinical features on the reversion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The clinical manifestations of CM have a high impact on the quality of life of patients, and monoclonal antibodies such as fremanezumab are used as prophylactic treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Diagnosed CM patients treated for at least 3 months with monthly fremanezumab were interviewed. The data to assess efficacy were before treatment and at the time of the interview: monthly headache days (MHDs), daily headache hours (DHHs), monthly symptomatic medication days (MSMDs), percentage of patients with symptomatic medication overuse (SMO), and pain intensity with the numerical rating scale (NRS) score. Possible predictors of reversion were analyzed: percentage of patients treated for at least 12 months, hypertension, diabetes mellitus, depression, anxiety, symptomatic control with non\u2010steroidal anti\u2010inflammatory drugs (NSAIDs), triptans or both, and amitriptyline prophylaxis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 54 patients were included, of whom 40 (74.1%) were converters to EM. There were significant improvements in converters compared to pre\u2010treatment in MHDs (28.0\u00a0vs. 5.0 days), as well as on the variables DHHs, MSMDs, and SMO. The percentage of erenumab failures was significantly higher in non\u2010converters than in converters, as was the percentage of patients with anxiety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>High reversion from CM to EM was achieved with fremanezumab and notable symptomatological improvement, establishing previous failure to erenumab and anxiety as possible detrimental factors for reversion.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/brb3.3631","type":"journal-article","created":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T22:59:20Z","timestamp":1721602760000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reversion of chronic to episodic migraine in working age and botulinum toxin\u2010resistant patients treated with fremanezumab: A real\u2010life study"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6911-1342","authenticated-orcid":false,"given":"Juan","family":"Tudela\u2010Tomas","sequence":"first","affiliation":[{"name":"Servicio de Farmacia Hospitalaria Hospital Universitario Puerta del Mar  Cadiz Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa\u2010Maria","family":"Ramos\u2010Guerrero","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia Hospitalaria Hospital Universitario Puerta del Mar  Cadiz Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria\u2010Eugenia","family":"Rodriguez\u2010Mateos","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia Hospitalaria Hospital Universitario Puerta del Mar  Cadiz Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,7,21]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415\u2010022\u201011226\u20104"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.10.1637"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072\u2010010\u20100269\u20106"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468\u20102982.2008.01819.x"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526\u20104610.2003.03068.x"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000058907.41080.54"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415\u2010012\u20106725\u2010x"},{"key":"e_1_2_11_9_1","article-title":"Reversion of patients with chronic migraine to an episodic migraine classification with fremanezumab treatment","author":"Cohen J. M.","year":"2018","journal-title":"The Journal of Headache and Pain"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11916\u2010010\u20100159\u2010x"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/164_2018_201"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417690488"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2018.01.008"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14472"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2009.01.002"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13997"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14097"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13642"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12201"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10194\u2010011\u20100388\u20103"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468\u20102982.2006.01172.x"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211048765"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526\u20104610.2006.00509.x"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709038"},{"key":"e_1_2_11_25_1","first-page":"70","article-title":"Reversion of patients with chronic migraine to an episodic migraine classification with fremanezumab treatment","volume":"58","author":"Singh R. B. H.","year":"2018","journal-title":"Headache"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194\u2010020\u201001208\u20100"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(15)60692\u20104"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468\u20102982.2003.00550.x"}],"container-title":["Brain and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/brb3.3631","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T12:53:14Z","timestamp":1722257594000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/brb3.3631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1002\/brb3.3631"],"URL":"https:\/\/doi.org\/10.1002\/brb3.3631","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/BRB3.3631\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.3631\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.3631\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.3631\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.3631\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.3631\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.3631\/v2\/response1","asserted-by":"object"}]},"ISSN":["2162-3279","2162-3279"],"issn-type":[{"value":"2162-3279","type":"print"},{"value":"2162-3279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"2024-01-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e3631"}}